Published in Curr Opin Lipidol on February 01, 2010
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf (2002) 1.24
The myotoxicity of statins. Curr Opin Lipidol (2002) 0.96
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs (2004) 0.96
Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol (2009) 0.95
Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol (2010) 0.85
Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J (2008) 0.82
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol (2003) 0.81
Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. Am J Cardiovasc Drugs (2011) 0.79
The future direction of cholesterol-lowering therapy. Curr Opin Lipidol (2002) 0.79
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough? Curr Opin Lipidol (2011) 0.77
A rare complication with a single dose of alendronate. BMJ Case Rep (2010) 0.77
Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes. Diab Vasc Dis Res (2005) 0.76
Diabetes and cardiovascular disease: new perspectives. Curr Opin Lipidol (2009) 0.75
Nutrition and metabolism. Curr Opin Lipidol (2008) 0.75
Atherosclerosis and lipoproteins: vascular cell senescence and atherosclerosis. Curr Opin Lipidol (2007) 0.75
Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol. Curr Opin Lipidol (2014) 0.75
Therapy and clinical trials: nicotinic acid in the management of atherosclerotic disease. Curr Opin Lipidol (2010) 0.75
Therapy and clinic trials. Curr Opin Lipidol (2007) 0.75
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management. Curr Opin Lipidol (2008) 0.75
Novel cardiovascular risk-assessment metrics and absolute risk assessment: future role in clinical practice? Curr Opin Lipidol (2014) 0.75
The onward march of PCSK9 inhibition. Curr Opin Lipidol (2017) 0.75
A potential role for monoclonal antibodies in clinical lipidology: can we look beyond statins? Curr Opin Lipidol (2013) 0.75
Inhibition of PCSK9: is this the way forward for managing residual risk? Curr Opin Lipidol (2012) 0.75
Management of homozygous familial hypercholesterolaemia. Curr Opin Lipidol (2014) 0.75
Statin/ezetimibe combination therapy: emerging evidence. Curr Opin Lipidol (2011) 0.75
Therapy and clinical trials: glycaemic control and cardiovascular disease. Curr Opin Lipidol (2009) 0.75
Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safety. Curr Opin Lipidol (2014) 0.75
Bariatric surgery and cardiovascular risk reduction. Curr Opin Lipidol (2014) 0.75
Estimation of cardiovascular risk using 10-year risk metric: time for a rethink? Curr Opin Lipidol (2012) 0.75
Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues? Curr Opin Lipidol (2016) 0.75
In defence of obsolete data. QJM (2010) 0.75
Therapy and clinical trials: Familial hypercholesterolaemia and prevention of coronary artery disease. Curr Opin Lipidol (2009) 0.75